Table 5.
Second- and Third-Line Grade 3 or 4 AEs
| Reference | Intervention | No. of Patients Analyzed (%) | Anemia No. (%) | Hypertension No. (%) | Neutropenia No. (%) | Febrile Neutropenia No. (%) | Leucopenia No. (%) | Thrombocytopenia No. (%) | Diarrhea No. (%) | Nausea No. (%) | Vomiting No. (%) | Fatigue No. (%) | Rash No. (%) | Neuropathy No. (%) | Overall AEs No. (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Garassino et al41 | Erlotinib | 107 | — | — | 0 (0.0) | 0 (0.0) | — | — | 3 (3.0) | 1 (1.0)a | — | NR | NR | 15 (14.0) | |
| Docetaxel | 104 | — | — | 21 (21.0) | 4 (4.0) | — | — | 2 (2.0) | 3 (3.0) | — | NR | NR | 7 (17.0)b; 8 (13.0)c | ||
| Shaw et al56 | Crizotinib | 172 | 4 (2.0) | — | 23 (13.0) | 1 (1.0) | — | — | 0 (0.0) | 1 (1.0) | 2 (1.0) | 4 (2.0) | 0 (0.0) | — | NR (33.0) |
| Chemotherapy (pemetrexed or docetaxel) | 171 | 9 (5.0) | — | 33 (19.0) | 16 (9.0) | — | — | 1 (1.0) | 2 (1.0) | 0 (0.0) | 7 (4.0) | 0 (0.0) | — | NR (32.0) | |
| Miller et al15 | Afatinib | 390 (67) | 9 (2.0) | — | — | — | — | — | 66 (17.0) | 8 (2.0) | 9 (2.0) | 23 (6.0) | 56 (14.0) | — | NR (10.0) |
| Hirsh et al16 | Placebo | 195 (33) | 1 (0.5) | — | — | — | — | — | 0 (0.0) | 0 (0.0) | 1 (0.5) | 3 (2.0) | 0 (0.0) | — | NR (< 0.1) |
| Quoix et al53 | Carboplatin plus taxol | 225 | 21 (9.4) | — | 108 (48.4) | 21 (9.4) | — | 15 (6.7) | 6 (2.7) | 6 (2.7) | — | — | 7 (3.1) | NR | |
| Vinorelbine or gemcitabine | 223 | 10 (4.4) | — | 28 (12.4) | 6 (2.7) | — | 2 (0.9) | 2 (0.9) | 2 (0.9) | — | — | 1 (0.4) | NR | ||
| Garon et al57 | Ramucirumab plus docetaxel | 627 | 18 (3.0) | 35 (6.0) | 306 (49.0) | 100 (16.0) | 86 (14.0) | 18 (3.0) | 29 (5.0) | 7 (1.0) | 8 (1.0) | 88 (14.0) | — | 17 (3.0) | 495 (79.0) |
| Placebo plus docetaxel | 618 | 35 (6.0) | 13 (2.0) | 246 (39.0) | 62 (10.0) | 77 (12.0) | 4 (1.0) | 19 (3.0) | 27 (1.0) | 12 (2.0) | 65 (10.0) | — | 10 (2.0) | 444 (71.0) |
Abbreviations: AE, adverse event; NR, not reported.
a
Nausea and vomiting.
b
Once per week.
c
Once every 3 weeks.